Table 11.6a

Immunosuppression Use for Induction, 1993 to 2002

Recipients with Heart Transplants

	Year of Transplant
	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002
Transplants	2,298	2,340	2,362	2,343	2,294	2,348	2,188	2,197	2,202	2,154
Tx With Immunosuppression Info	2,276	2,328	2,304	2,051	2,268	2,321	2,137	2,143	2,148	2,090
No Induction Drugs Recorded	88.0%	64.1%	64.9%	68.7%	70.2%	70.6%	65.7%	62.9%	56.5%	55.2%
Drugs	0.0%	0.0%	0.0%	-	-	-	-	-	-	-
ALG
ATG	0.3%	16.0%	16.6%	14.7%	14.6%	13.5%	10.8%	9.2%	7.7%	7.1%
NRATG/NRATS	0.0%	0.0%	0.2%	2.2%	3.4%	3.4%	1.3%	0.1%	-	-
OKT3	11.7%	20.1%	18.7%	14.6%	12.4%	9.9%	11.1%	8.7%	8.6%	5.4%
Thymoglobulin	-	-	-	-	0.0%	0.0%	2.5%	7.0%	10.8%	16.3%
Zenapax	-	-	-	-	-	2.9%	7.3%	8.9%	13.3%	11.1%
Simulect	0.0%	0.0%	0.0%	0.0%	0.0%	0.2%	2.5%	5.1%	5.2%	7.0%

Source: OPTN/SRTR Data as of August 1, 2003.

(-) = Drug not used anytime during the year.

Induction drugs include any reported antilymphocyte antibodies and antibodies directed against lymphocyte receptors.